News and Trends 15 Dec 2022
MinervaX raises €72M to develop Group B Streptococcus vaccine
MinervaX ApS, a privately held Danish biotech company developing a novel vaccine against Group B Streptococcus (GBS), has completed a €72 million ($76.5 million) financing round. The equity financing of…